GLIPIZIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Glipizide, and what generic alternatives are available?
Glipizide is a drug marketed by Aurobindo Pharma, Mylan, Par Pharm, Unique, Watson Labs, Zydus Pharms, Accord Hlthcare, Ani Pharms, Apotex, Aurobindo Pharma Usa, Barr Labs Inc, Chartwell Rx, Oxford Pharms, Rubicon, Sandoz, Sun Pharm Inds Inc, Watson Labs Teva, Dash Pharms, Epic Pharma Llc, Heritage Pharms, Teva Pharms, and Zydus Pharms Usa Inc. and is included in twenty-six NDAs.
The generic ingredient in GLIPIZIDE is glipizide; metformin hydrochloride. There are eighteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the glipizide; metformin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Glipizide
A generic version of GLIPIZIDE was approved as glipizide; metformin hydrochloride by EPIC PHARMA LLC on October 27th, 2005.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for GLIPIZIDE?
- What are the global sales for GLIPIZIDE?
- What is Average Wholesale Price for GLIPIZIDE?
Summary for GLIPIZIDE
| US Patents: | 0 |
| Applicants: | 22 |
| NDAs: | 26 |
| Finished Product Suppliers / Packagers: | 40 |
| Raw Ingredient (Bulk) Api Vendors: | 123 |
| Clinical Trials: | 42 |
| Patent Applications: | 4,324 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for GLIPIZIDE |
| Drug Sales Revenues: | Drug sales revenues for GLIPIZIDE |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for GLIPIZIDE |
| What excipients (inactive ingredients) are in GLIPIZIDE? | GLIPIZIDE excipients list |
| DailyMed Link: | GLIPIZIDE at DailyMed |
Recent Clinical Trials for GLIPIZIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Memorial Sloan Kettering Cancer Center | Phase 2 |
| University of Michigan | Phase 1 |
| Food and Drug Administration (FDA) | Phase 1 |
Pharmacology for GLIPIZIDE
| Drug Class | Sulfonylurea |
Medical Subject Heading (MeSH) Categories for GLIPIZIDE
Anatomical Therapeutic Chemical (ATC) Classes for GLIPIZIDE
US Patents and Regulatory Information for GLIPIZIDE
GLIPIZIDE is protected by zero US patents and one FDA Regulatory Exclusivity.
FDA Regulatory Exclusivity protecting GLIPIZIDE
COMPETITIVE GENERIC THERAPY
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm Inds Inc | GLIPIZIDE | glipizide | TABLET;ORAL | 077820-001 | Jul 11, 2006 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Mylan | GLIPIZIDE | glipizide | TABLET;ORAL | 074438-001 | Jun 20, 1995 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Dash Pharms | GLIPIZIDE AND METFORMIN HYDROCHLORIDE | glipizide; metformin hydrochloride | TABLET;ORAL | 078083-003 | Apr 12, 2007 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Teva Pharms | GLIPIZIDE AND METFORMIN HYDROCHLORIDE | glipizide; metformin hydrochloride | TABLET;ORAL | 077270-002 | Oct 28, 2005 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Watson Labs Teva | GLIPIZIDE | glipizide | TABLET;ORAL | 074223-001 | Feb 27, 1995 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Epic Pharma Llc | GLIPIZIDE AND METFORMIN HYDROCHLORIDE | glipizide; metformin hydrochloride | TABLET;ORAL | 077507-001 | Oct 27, 2005 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
